IVF Firm's XRP Trade Wins, SOL Bet Sits Underwater

Highlights

NewGenIvf (NASDAQ: NIVF) bought and fully sold 146,432 XRP during 2025, clearing a $10,849 gain
Its 13,000.23 SOL position carries a cost basis of $2,906,222 against a year-end fair value of $1,630,827 — an unrealized loss of roughly $1.28 million
The company separately announced plans to invest up to $30 million staking SOL, funded through existing credit facilities
Digital assets are explicitly framed as a treasury diversification play, not a shift in the company's core IVF business

NewGenIvf Group, a Nasdaq-listed fertility technology company trading under the ticker NIVF, disclosed in its annual report filed with the SEC that it bought 146,432 XRP at some point during 2025 and sold the entire position before year-end, booking a gain of $10,849. Its bet on Solana went the other way: the company's 13,000.23 SOL, carried at a cost basis of $2,906,222, was worth $1,630,827 at year-end, an unrealized loss of roughly $1.28 million.

The filing is a small but clear example of how public companies with no obvious connection to crypto are quietly building token treasuries and reporting the results with the same plain accounting language they'd use for any other financial instrument. NewGenIvf's core business is in-vitro fertilization services; the company states explicitly that its digital asset activity is not part of its core operations and that it does not engage in mining, staking, lending or other yield-generating crypto activities with these particular holdings — despite having separately floated a much larger staking plan.

That plan is the more interesting thread here. In June 2025, NewGenIvf announced it would invest up to $30 million staking SOL, funded through existing credit facilities of $26 million and $100 million with ATW and White Lion respectively. That figure dwarfs the roughly $2.9 million cost basis disclosed for its actual SOL holdings at year-end, meaning the company has so far deployed only a small fraction of the capital it said it was prepared to commit — a gap worth watching if it expands the position and SOL's price has since moved further from its 2025 entry point.

The XRP and SOL results tell two different stories about timing. Selling all 146,432 XRP for a modest but positive return suggests the company caught a favorable window on the token, even if the total dollar gain is negligible next to a $30 million staking ambition. The SOL position tells the opposite story: a treasury allocation made at a cost basis nearly double its year-end market value, which is the kind of outcome that makes headlines specifically because the buyer is a fertility company rather than a crypto-native fund.

Corporate treasuries dabbling in digital assets outside of crypto or fintech is no longer a novelty, but the mixed results here are a useful data point against the narrative that any public company holding crypto is automatically sitting on gains. NewGenIvf's disclosure shows a company netting a small win on one token while carrying a seven-figure paper loss on another, filed in the same routine annual report — a reminder that treasury-level crypto bets carry the same timing risk for a fertility clinic operator as they do for anyone else.

Whether NewGenIvf follows through on the full $30 million SOL staking plan, and at what price, will likely determine whether this turns into a bigger story or stays a footnote in a company whose primary business has nothing to do with digital assets. For now, it sits alongside a wider trend of non-crypto public companies making concentrated, sometimes abrupt, token allocation decisions and a broader pattern of XRP's own price swings drawing in opportunistic corporate buyers and sellers alike.